Leaving No One Behind: Community-driven Approaches To Eliminate HIV In Australia
Funder
National Health and Medical Research Council
Funding Amount
$1,562,250.00
Summary
Eliminating HIV from Australia is possible with effective HIV prevention methods like treatment as prevention (TasP) and pre-exposure prophylaxis (PrEP). However there are inequities in our HIV response with declines of new infections in Australian-born men who have sex with men but not in overseas-born Australian men. This program uses crowdsourcing (sharing solutions from the community to eliminate HIV) and evaluates the value of the proposed solutions, to inform HIV policy.
HIV incidence remains exceptionally high in young South African women. I will leverage samples collected during two funded clinical studies in South Africa to investigate the relationships between female reproductive tract inflammation, microbiome communities and function, contraceptive use and HIV acquisition. This study will improve our understanding of the factors that influence HIV infection in this key population, as well as HIV incidence globally.
The Elimination Of Viral Hepatitis And Ending HIV/AIDS As Global Health Threats.
Funder
National Health and Medical Research Council
Funding Amount
$2,114,215.00
Summary
Over the next five years my research will focus on reducing the impact of blood-borne viruses (BBVs), , particularly HCV, in vulnerable populations. Using innovative surveillance systems, research methods, implementation science and mathematical modelling, I will study BBV transmission and develop interventions to reduce it and associated risk behaviours (drug and alcohol use and sexual risk) and increase testing and treatment. My work will advance elimination of BBVs as public health threats.
Developing Robust Biomarkers For Vascular Cognitive Impairment And Dementia: Adding V To The ATN Research Framework
Funder
National Health and Medical Research Council
Funding Amount
$3,289,215.00
Summary
The main objective of this research is to develop biomarkers for vascular dementia. It builds upon the longitudinal studies and international consortia that I lead. The studies will use multimodal MRI, advanced retinal imaging, mass spectrometry and other techniques to establish and validate robust biomarkers of vascular contributions to dementia. The findings will help achieve a definitive diagnosis of vascular dementia and quantify vascular pathology in someone with dementia.
Prediction Of Fracture By Clinico-genetic Profiling
Funder
National Health and Medical Research Council
Funding Amount
$2,339,215.00
Summary
The loss of bone with advancing age is the main cause of osteoporosis and bone fracture. Bone loss is highly variable between individuals, and we are not sure why. I want to find out factors that contribute to bone loss, and then use this knowledge to identify individuals at high risk of excessive bone loss for early prevention. My goal over the next 5 years is to create a new clinico-genetic model for assessing the rate of bone loss, and predicting the risk of fracture for an individual.
A Risk Stratification Tool For The Prevention Of Avoidable Perinatal Mortality And Morbidity
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Stillbirth is more common in Australia than in some high-income countries. Babies born early may experience lung or other problems. Many current stillbirths and preterm birth can be prevented. Using a cohort of >4.5 million births from WA, NSW, SA and NT (N >4.5 million), this project will develop a strategy to predict the risk of stillbirth, preterm birth, and low birth weight. Better identification of risk in pregnancy will improve antenatal care to reduce stillbirth and neonatal morbidi ....Stillbirth is more common in Australia than in some high-income countries. Babies born early may experience lung or other problems. Many current stillbirths and preterm birth can be prevented. Using a cohort of >4.5 million births from WA, NSW, SA and NT (N >4.5 million), this project will develop a strategy to predict the risk of stillbirth, preterm birth, and low birth weight. Better identification of risk in pregnancy will improve antenatal care to reduce stillbirth and neonatal morbidity.Read moreRead less
Healthy Lungs For Life: A Life Course Approach To Reduce COPD
Funder
National Health and Medical Research Council
Funding Amount
$2,491,398.00
Summary
Chronic Obstructive Lung Disease (COPD) causes breathing distress, disability and premature death. I have shown that COPD mostly has its origins in childhood. This means we can now identify early life risk factors to prevent COPD or help us catch it early, to improve health. My 5-year vision is to reduce the dire burden of COPD by creating evidence to change guidelines and policy and facilitating the transfer of that knowledge to practice.
Reducing Colorectal Cancer Burden In Young Adults: Precision Prevention And Early Detection
Funder
National Health and Medical Research Council
Funding Amount
$1,449,800.00
Summary
Bowel cancer rate in young adults before age 50 is increasing worldwide including Australia. Since it is impossible to screen everyone, it is critical to identify who is likely to develop the disease, to optimise screening. Using the world's largest resource for young-onset bowel cancer, I will conduct studies to generate high-quality evidence to inform how to best prevent bowel cancer in young adults and translate into the policy and practice, to reduce colorectal cancer burden in young adults.
Atypical femoral fractures (AFF) are uncommon, but catastrophic, complications of the anti-osteoporosis medications, bisphosphonates. We aim to identify patients either protected from, or at risk of, AFF by identifying changes in their bone geometry, structure and quality, and genes increasing risk of these fractures. In this way, these cheap and effective anti-osteoporosis treatments can be targeted to patients at the lowest risk of AFF and alternative treatments to those at highest risk.
Personalised Risk-directed Clot Prevention For Patients With Cancer
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Blood clots are a leading cause of death among cancer patients, second only to cancer itself. This EL1 program includes clinical and laboratory studies to assess the impact of personalised clot prevention for patients receiving cancer treatments in ambulatory care settings. Laboratory studies and evaluation of outcomes among ‘real-world’ patients with cancers at high risk of developing blood clots, will improve understanding of both clots and cancer, to advance research and clinical practice.